Research programme: antivirals - Gilead Sciences

Drug Profile

Research programme: antivirals - Gilead Sciences

Alternative Names: Acyclic nucleoside phosphonates - Gilead Sciences; GS 327073; GS 8374; GS 9224; N4-acyl derivatives of cidofovir - Gilead

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Gilead Sciences; Institute of Organic Chemistry and Biochemistry (Prague); Rega Institute for Medical Research
  • Class Nucleotides; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; HIV integrase inhibitors; HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Viral infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Viral-infections in Europe
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Viral-infections in USA
  • 03 May 2007 Preclinical trials in Viral infections in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top